Skandinaviska Enskilda Banken (SEB)
AKRO

Skandinaviska Enskilda Banken (SEB)’s Akero Therapeutics AKRO Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-7,676
Closed -$410K – 790
2025
Q2 		$410K Hold
7,676
– – ﹤0.01% 714
2025
Q1 		$311K Buy
+7,676
New +$325K ﹤0.01% 722

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
GA
General Atlantic New York $2.91B AUM 24.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s AKRO Position: Q3 2025 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Akero Therapeutics (AKRO) in Q3 2025, closing a stake of 7,676 shares — an estimated $410K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in AKRO in Q1 2025 and held it in 2 quarters. The position peaked at $410K in Q2 2025. 265 funds tracked by Wall St. Rank hold AKRO as of Q3 2025.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Akero Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 7,676 Akero Therapeutics shares in Q3 2025, an estimated $410K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Akero Therapeutics in Q1 2025 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Akero Therapeutics position peaked at $410K in Q2 2025.
  • 265 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2025.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q3 2025, filed 7 Nov 2025.